Halton J M, Atkinson S A, Barr R D
Department of Pediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada.
Int J Cancer Suppl. 1998;11:81-4.
Severely malnourished children afflicted by acute lymphoblastic leukemia (ALL), particularly in developing countries, have reduced tolerance to chemotherapy and a compromised prospect for survival. We investigated the prevalence and severity of alterations in growth and nutritional status in children with ALL from population-based referral areas in Canada. All children were treated with Dana-Farber Cancer Institute ALL Consortium protocols. First, the relative impact of cranial irradiation (CI) and chemotherapy on growth was studied in 116 children at diagnosis and at 6-month intervals during treatment. We observed a decline in height standard deviation (SD) score in the first year in all children, and a further decline in height SD score during the second year only in the children who received CI. Weight reduction occurred in the first year, but during the second year there was a disproportionate increase in weight compared with height, suggesting that children treated with ALL have a tendency toward obesity. Both chemotherapy and CI contribute to the altered growth observed in children treated for ALL. Second, intestinal functional integrity was assessed in 16 children during post-induction chemotherapy. Nutrient intake was adequate and there was minimal evidence of malabsorption: fat malabsorption occurred in only 1 child (after treatment-related pancreatitis), abnormal D-xylose absorption occurred in 2 children at 6 months of therapy (returning to normal 6 months later) and abnormal lactose absorption occurred in 4 children. Third, weight, height, whole body lean and fat mass measured by dual-energy X-ray absorptiometry and serum albumin were determined at diagnosis and at 6-month intervals throughout therapy in 19 children with ALL. Height SD scores decreased significantly during treatment. Serum albumin was abnormally low in 6/19 at diagnosis and 14/18 during intensive consolidation therapy. The mean change in the ratio of lean mass to total body weight showed a 5% reduction by 6 months of therapy. Body fat increased from a mean of 22% at diagnosis to 28% at completion of therapy. The majority of children treated for ALL thus have significant changes in nutritional status manifested by reductions in growth, alterations in lean and fat body mass and abnormally low serum proteins during intensive therapy.
患有急性淋巴细胞白血病(ALL)的严重营养不良儿童,尤其是在发展中国家,对化疗的耐受性降低,生存前景堪忧。我们调查了来自加拿大基于人群的转诊地区的ALL患儿生长和营养状况改变的患病率及严重程度。所有患儿均按照达纳-法伯癌症研究所ALL联盟方案进行治疗。首先,在116名患儿诊断时及治疗期间每隔6个月研究头颅照射(CI)和化疗对生长的相对影响。我们观察到所有患儿在第一年身高标准差(SD)评分下降,而仅在接受CI的患儿中,第二年身高SD评分进一步下降。体重在第一年减轻,但在第二年体重相对于身高出现不成比例的增加,这表明接受ALL治疗的患儿有肥胖倾向。化疗和CI均导致接受ALL治疗的患儿出现生长改变。其次,在诱导化疗后对16名患儿的肠道功能完整性进行评估。营养摄入充足,吸收不良的证据极少:仅1名患儿出现脂肪吸收不良(治疗相关胰腺炎后),2名患儿在治疗6个月时出现异常的D-木糖吸收(6个月后恢复正常),4名患儿出现异常的乳糖吸收。第三,在19名ALL患儿诊断时及整个治疗过程中每隔6个月通过双能X线吸收法测量体重、身高、全身瘦体重和脂肪量,并测定血清白蛋白。治疗期间身高SD评分显著下降。诊断时19名患儿中有6名血清白蛋白异常低,强化巩固治疗期间18名患儿中有14名异常低。治疗6个月时,瘦体重与总体重之比的平均变化显示下降了5%。体脂从诊断时的平均22%增加到治疗结束时的28%。因此,大多数接受ALL治疗的患儿在强化治疗期间营养状况有显著变化,表现为生长发育迟缓、瘦体重和脂肪量改变以及血清蛋白异常低。